Stock Comparison

BSX vs JNJ

Boston Scientific Corp vs Johnson & Johnson

Who's the better investment? Let's break it down.

The Verdict

JNJ takes this one.

This one's close — only 0.9 points separating them. JNJ wins by a hair, but both deserve a closer look.

BSX

Boston Scientific Corp

0.1

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Want to compare any two stocks?

Valuation

BSX

Metric

JNJ

$79.7B

Market Cap

$557.1B

22.4

P/E Ratio

Lower may indicate better value

26.5

17.6

Forward P/E

28.4

Profitability & Growth

BSX

Metric

JNJ

17.3%

Profit Margin

21.8%

69.1%

Gross Margin

68.0%

18.4%

Operating Margin

25.9%

12.6%

Return on Equity

26.3%

6.9%

Return on Assets

10.7%

17.4%

Revenue Growth

7.9%

$2.38

EPS

$8.65

Financial Health

BSX

Metric

JNJ

0.5

Debt-to-Equity

Lower = less leverage

0.6

1.6

Current Ratio

Above 1.0 is healthy

1.0

0.6

Beta

Lower = less volatile

0.3

None

Dividend Yield

2.3%

Risk Comparison

BSX

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Medium

Regulatory

Medium

What Could Go Wrong

The proposed Penumbra acquisition, while strategic, carries integration risks and could lead to higher-than-expected costs or slower-than-expected synergies, potentially impacting profitability and ma...

Red Flags

🚩Slight revenue miss in Q1 2026, though organic growth remains strong.
🚩Limited specific balance sheet and cash flow details in provided real-time intelligence, requiring r...
🚩No clear analyst consensus or institutional ownership percentage in provided data.

JNJ

Overall

Conservative

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for JNJ, despite its broad diversification, remains its exposure to patent expirations and increasing biosimilar competition for blockbuster drugs like Stelara, which generated over $...

Red Flags

🚩Deceleration of organic revenue growth below 4% for two consecutive quarters, signaling broader mark...
🚩Significant increase in litigation provisions or adverse judgments exceeding $5 billion in a single ...
🚩Dividend growth rate significantly slowing or pausing, indicating a fundamental shift in capital all...

Competitive Moat

BSX

Rating

🛡️ Narrow

Trend

➡️ Stable to Expanding

Intangible Assets/IP (patents, regulatory approvals)Switching Costs (physician familiarity, integration into hospital systems)Efficient Scale (high R&D and regulatory costs favor large players)

JNJ

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets (Patents, Brand Recognition for pharmaceutical products, consumer brands, and medical devices)Switching Costs (High for complex medical devices and established drug therapies, particularly in hospital settings)Efficient Scale (Massive global R&D, manufacturing, and distribution infrastructure)

Investment Thesis

BSX0.1/10

Boston Scientific represents a stable, growing investment in the medical device sector, benefiting from an aging population and increasing demand for minimally invasive procedures. Its strategic acquisition of Penumbra and consistent organic growth in key segments position it for continued moderate capital appreciation and market leadership, though not 10x exponential growth.

Full BSX Analysis

JNJ1.0/10

If Johnson & Johnson continues to deliver consistent mid-single-digit organic revenue growth, driven by key pharmaceutical products and strategic MedTech innovation, while maintaining its strong dividend and capital allocation discipline, then its valuation should remain stable or grow modestly, providing a reliable long-term investment for income and capital preservation. This thesis focuses on s...

Full JNJ Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

BSX0.1/10

Boston Scientific (BSX) is a well-established large-cap medical device company. While it demonstrates solid financial health and consistent, healthy operational growth (Q1 2026 revenue +11.6% reported, +9.4% organic) and strategic acquisitions (like the proposed Penumbra deal), its fundamental profile is misaligned with 10x growth potential within 3-5 years. A market capitalization of $80.16 billion would need to reach over $800 billion for a 10x return, which is highly improbable for a company ...

Full BSX Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555.59 billion fundamentally restricts its ability to achieve 10x growth within a 3-5 year timeframe. Su...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.